证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-073 丽珠医药集团股份有限公司关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 丽珠医药集团股份有限公司（以下简称"公司"）于 2024 年 12 月 24 日召 开了公司 2024 年第四次临时股东大会、2024 年第二次 A 股类别股东会及 2024 年第二次 H 股类别股东会，审议通过了《关于回购公司部分 A 股股份方案的议 案》，于 2025 年 5 月 29 日召开了公司 2024 年度股东大会、2025 年第一次 A 股 类别股东会及 2025 年第一次 H 股类别股东会，审议通过了《关于继续实施回购 公司部分 A 股股份方案的议案》及《关于授予董事会回购本公司 H 股的一般授 权》。现将公司回购股份的进展情况公告如下： 一、回购 A 股股份的进展情况 根据公司于 2024 年 12 月 25 日披露的《丽珠医药集团股份有限公司回购报 告书》（公告编号：2024-079），公司将以不低于人民币 60,000.00 万元（含）， 不超过人民 ...

格隆汇12月1日丨丽珠医药(01513.HK)发布公告，截至2025年11月30日，公司通过集中竞价交易方式回 购了公司A股股份共计1619.33万股，占公司总股本的比例为1.79%，购买的最高价为人民币41.99元/ 股，最低价为人民币33.21元/股，已使用的资金总额为人民币6.002亿元(不含交易费用)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司關於回購公司股份的進展公告》，僅供參閱。 海外監管公告 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* 公司秘書 劉寧 丽珠医药集团股份有限公司（以下简称"公司"）于 2024 年 12 月 24 日召 开了公司 2024 年第四次临时股东大会、2024 年第二次 A 股类别股东会及 2024 年第二次 H 股类别股东会，审议通过了《关于回购公司部分 A 股股份方案的议 案》，于 2025 年 5 月 29 日召开了公司 2024 年度股东大会、2025 年第一次 A 股 类别股东会及 2025 年第一次 H 股类别股东会，审议通过了《关于继续实施回购 公司部分 A 股股份方案的议案》及《 ...

Core Viewpoint - Lijun Group's P-CAB product JP-1366 has been submitted for market approval for tablet form in July 2024, and the injection form has entered Phase II clinical trials in October, marking it as the first P-CAB drug in China to conduct research on injection form [1] Group 1: Product Development - The company is leveraging its established product portfolio and sales channels in the gastrointestinal field to accelerate market penetration of JP-1366 [1] - JP-1366 is expected to create a synergistic effect with existing PPI products [1] Group 2: Market Potential - The P-CAB market is experiencing rapid growth, with projected domestic sales reaching approximately 1.25 billion in 2024, representing an 81% year-on-year increase [1]

Group 1: R&D Progress and Market Position - The LZM012 project has completed Phase III clinical trials for psoriasis and ankylosing spondylitis, with a formal market application expected next month for psoriasis and in the first half of next year for ankylosing spondylitis [2][3] - LZM012 is the first domestic Phase III study targeting psoriasis with PASI100 as the primary endpoint, showing superior efficacy compared to existing treatments, with fewer administration cycles and lower overall costs [2][3] - The JP-1366 tablet of the P-CAB product has been submitted for market approval, with the injection form entering Phase II clinical trials, capitalizing on the growing P-CAB market projected to reach approximately CNY 1.25 billion in 2024, an 81% year-on-year increase [3][4] Group 2: Strategic Product Development - The company is focusing on the schizophrenia long-acting injection market, with the recently approved aripiprazole microsphere being the first of its kind in China, included in the 2025 guidelines for schizophrenia treatment [4][5] - The company is advancing a new generation KCNQ2/3 activator, NS-041, which is a first-class new drug with unique molecular design, targeting both epilepsy and depression indications [5] - The company has established a comprehensive product pipeline for GnRH-a long-acting release formulations, with the approval of the first microsphere product and plans for further submissions, enhancing treatment options for various conditions [6][7] Group 3: Financial Health and Strategic Acquisitions - The company maintains a robust cash reserve, allowing for dividends, buybacks, daily operations, R&D investments, and potential strategic acquisitions [8][9] - A planned acquisition of a Vietnamese company is underway, marking the first acquisition of a Vietnamese pharmaceutical company by a Chinese enterprise, with ongoing compliance with local regulations [9] - The company aims to focus on strategic partnerships in areas such as digestion, mental health, cardiovascular, metabolic, and autoimmune diseases, targeting projects with patent barriers and commercialization potential [9]

Core Insights - The company focuses on sustainable development through R&D innovation and internationalization, enhancing its presence in "strong advantages" and "high potential chronic disease" sectors, particularly in digestion, mental health, cardiovascular, metabolism, and autoimmune fields [1] Investment Highlights - The company maintains a "buy" rating and raises the target price to CNY 49.13 per share from CNY 43.96. Projected revenues for 2025-2027 are CNY 120.36 billion, CNY 123.95 billion, and CNY 130.29 billion, with growth rates of 1.9%, 3.0%, and 5.1% respectively. Net profits are forecasted at CNY 22.21 billion, CNY 22.95 billion, and CNY 23.91 billion, with growth rates of 7.7%, 3.4%, and 4.2%. EPS is expected to be CNY 2.46, CNY 2.54, and CNY 2.64 [2] R&D Pipeline Progress - The company reports significant advancements in its R&D pipeline. In the digestion sector, the P-CAB product JP-1366 tablet has been submitted for market approval, and the injection form has completed the first patient enrollment in Phase II. In the autoimmune sector, the IL-17A/F psoriasis and ankylosing spondylitis indications have completed Phase III trials, with psoriasis expected to be submitted for approval this year. In the mental health sector, the NS-041 tablet for epilepsy has completed Phase II enrollment, and the IND application for depression has been accepted. The new indication for Triptorelin microspheres for central precocious puberty has completed Phase III enrollment. Additionally, a new oral GnRH antagonist project for assisted reproduction is preparing for Phase II trials, and a quadrivalent influenza recombinant protein vaccine has completed Phase I enrollment. The semaglutide diabetes indication is expected to be approved this year, with the weight loss indication in late Phase III trials [3] International Expansion - The company is enhancing its overseas business layout, particularly in Vietnam, where a company acquisition is under approval. The target company, Imexpharm, has shown stable performance with over 20% growth in revenue, profit, and EBITDA. Imexpharm has the largest EU-GMP product line in Vietnam, and both companies are planning product and process transfers to leverage Imexpharm's established market channels and EU-GMP certification for expanding innovative drug products into overseas markets [3] Catalysts - Key catalysts include the ramp-up of new product volumes, clinical data from innovative drug pipelines, and external collaborations for licensing innovative drug pipelines [4]

Core Points - The company has nominated Ms. Wang Zhiyao as an independent non-executive director candidate for the 11th Board of Directors, pending approval at the shareholders' meeting [1] - Ms. Wang has completed the required independent director training and obtained the necessary certification recognized by the Shenzhen Stock Exchange [2] - The qualifications and independence of the independent director candidate have been reviewed and approved by the Shenzhen Stock Exchange without any objections [2] Summary by Sections - **Nomination of Independent Director**: The company held a board meeting on November 10, 2025, where it approved the nomination of Ms. Wang Zhiyao as an independent non-executive director candidate, subject to shareholder approval [1] - **Training Certification**: As of the date of the first extraordinary shareholders' meeting notification, Ms. Wang had not yet obtained the independent director training certification. However, she has since completed the training and received the certification [2] - **Regulatory Compliance**: The independent director candidate's qualifications and independence have been filed and reviewed by the Shenzhen Stock Exchange, confirming no issues [2]

Core Viewpoint - Lijun Group (000513.SZ) has announced that Ms. Wang Zhiyao has completed the recent independent director pre-appointment training (online) and has obtained the training certificate recognized by the Shenzhen Stock Exchange [1] Group 1 - The company has received notification from Ms. Wang Zhiyao regarding her participation in the independent director training [1] - The training was conducted online and is recognized by the Shenzhen Stock Exchange [1] - The completion of this training is a step towards enhancing corporate governance within the company [1]

Core Points - Lijun Group announced the nomination of Ms. Wang Zhiyao as an independent non-executive director candidate for the 11th Board of Directors [2] - The proposal will be submitted for approval at the upcoming shareholders' meeting, with her term starting from the date of approval until the end of the current board's term [2] - Ms. Wang has completed the required training for independent directors and has received certification recognized by the Shenzhen Stock Exchange [2] - The qualifications and independence of the independent director candidate have been reviewed and approved by the Shenzhen Stock Exchange without any objections [2]

Core Viewpoint - The company has nominated Ms. Wang Zhiyao as an independent non-executive director candidate, pending approval at the upcoming shareholders' meeting [1] Group 1: Board Meeting and Nomination - The company's board of directors will hold its 28th meeting of the 11th session on November 10, 2025, to review the nomination of Ms. Wang Zhiyao [1] - The nomination requires approval from the company's shareholders and will be effective from the date of approval until the end of the 11th board session [1] Group 2: Training and Qualifications - As of the date of the notice for the first extraordinary shareholders' meeting in 2025, Ms. Wang has not yet obtained the independent director training certification [1] - Ms. Wang has committed to participate in the most recent independent director pre-appointment training and has obtained the necessary certification recognized by the Shenzhen Stock Exchange [1] - The qualifications and independence of the independent director candidate have been reviewed and approved by the Shenzhen Stock Exchange without any objections [1]